{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"INTREPId","nct_id":"NCT04025372","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=intrepid-nct04025372. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"* Bicalutamide is administered orally on a daily basis\n* GnRH Agonist as prescribed\n* Radiation therapy is administered starting 4-16 weeks after ADT","label":"Bicalutamide+GnRH Agonist+Radiation Therapy","type":"EXPERIMENTAL"},{"description":"* Darolutamide is administered orally twice daily\n* Radiation therapy is administered starting 4-16 weeks after Darolutamide","label":"Darolutamide+Radiation Therapy","type":"EXPERIMENTAL"}],"collaborators":["Bayer","Decipher Biosciences"],"completion_date":{"date":"2028-03-01","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":234,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Bicalutamide","otherNames":[],"type":"DRUG"},{"name":"GnRH Agonist","otherNames":[],"type":"DRUG"},{"name":"Radiation Therapy","otherNames":[],"type":"RADIATION"},{"name":"Darolutamide","otherNames":[],"type":"DRUG"}],"last_update":"2025-12-15","lead_sponsor":"Brigham and Women's Hospital","official_title":"INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-10-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"The percentage of patients with a PSA nadir <= 0.5","timeFrame":"6 months from end of treatment"}],"references":[{"citation":"Roy A, Green O, Brenneman R, Bosch W, Gay HA, Michalski JM, Baumann BC. Assessing Inter-Fraction Changes in The Size and Position of The Penile Bulb During Daily MR-Guided Radiation Therapy to The Prostate Bed: Do We Need to Adjust How We Plan Radiation in The Post-Radical Prostatectomy Setting to Reduce Risk of Erectile Dysfunction? Clin Genitourin Cancer. 2022 Jun;20(3):e227-e232. doi: 10.1016/j.clgc.2022.01.006. Epub 2022 Jan 11.","pmid":"35153154","type":"DERIVED"}],"start_date":{"date":"2020-06-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"INTREPId (INTermediate Risk Erection PreservatIon Trial)","url":"https://clinicaltrials.gov/study/NCT04025372"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/intrepid-nct04025372"}